Medicine, Hematology Oncology Division

Fingerprint Dive into the research topics where Medicine, Hematology Oncology Division is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.

Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences
Acute Myeloid Leukemia Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Profiles

No photo of Kehinde Adekola

Kehinde Adekola

Person: Academic

20122022
No photo of Mark Agulnik

Mark Agulnik

Person: Academic

20012023
No photo of Jessica K Altman

Jessica K Altman

Person: Academic

20052024

Research Output 1956 2019

1 Citation (Scopus)

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Formisano, L., Lu, Y., Servetto, A., Hanker, A. B., Jansen, V. M., Bauer, J. A., Sudhan, D. R., Guerrero-Zotano, A. L., Croessmann, S., Guo, Y., Ericsson, P. G., Lee, K. M., Nixon, M. J., Schwarz, L. J., Sanders, M. E., Dugger, T. C., Cruz, M. R., Behdad, A., Cristofanilli, M., Bardia, A. & 11 others, O’Shaughnessy, J., Nagy, R. J., Lanman, R. B., Solovieff, N., He, W., Miller, M., Su, F., Shyr, Y., Mayer, I. A., Balko, J. M. & Arteaga, C. L., Dec 1 2019, In : Nature communications. 10, 1, 1373.

Research output: Contribution to journal › Article

Open Access
breast
inhibitors
cancer
Breast Neoplasms
Protein-Tyrosine Kinases

A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation

Kamath, S. D., Lin, X. & Kalyan, A., Feb 1 2019, In : Oncologist. 24, 2, p. 151-156 6 p.

Research output: Contribution to journal › Article

Biliary Tract Neoplasms
Mutation
Adenocarcinoma
Neoplasms
Paraffin
4 Citations (Scopus)

Activation of MAPK Signaling by CXCR7 leads to enzalutamide resistance in prostate cancer

Li, S., Fong, K. W., Gritsina, G., Zhang, A., Zhao, C., Kim, J., Sharp, A., Yuan, W., Aversa, C., Yang, X. J., Nelson, P. S., Feng, F. Y., Chinnaiyan, A. M., De Bono, J. S., Morrissey, C., Rettig, M. B. & Yu, J., Jan 1 2019, In : Cancer Research. 79, 10, p. 2580-2592 13 p.

Research output: Contribution to journal › Article

Prostatic Neoplasms
Castration
Androgen Receptor Antagonists
MDV 3100
Androgen Antagonists

Grants 1996 2027

VA IPA FY20 for Elspeth Beauchamp

Platanias, L. C.

Jesse Brown VA Medical Center

10/1/19 → 9/30/20

Project: Research project

Immunoprecipitation
Immunoblotting
Small Interfering RNA
Transfection
Phosphotransferases

Prot #A18-15331: A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes

Altman, J. K.

Theradex, Aprea Therapeutics AB

9/26/19 → 9/26/22

Project: Research project

Prot #CA224083: A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 T

Chandra, S.

Bristol-Myers Squibb Company

9/25/19 → 9/25/22

Project: Research project